Sponsors developing a bispecific antibody may need to conduct a clinical study comparing the therapy to an approved monospecific antibody that targets the same antigens, FDA notes in draft guidance.
"In many situations, the clinical studies for bispecific antibodies will compare the bispecific antibody to standard of care or placebo,"...






